Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Uterine Cervical Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Leukemia, Hairy Cell 1Leukemia 1Kidney Neoplasms 1Hypoxia 1Health Status Unknown 1Colonic Neoplasms 1Carcinoma in Situ 1Brain Neoplasms 1Anus Neoplasms 1

Interventions

fludarabine phosphate 4Cyclophosphamide 4blinatumomab 3Rituximab 3Lenalidomide 2Immunotherapy, Adoptive 2venetoclax 1trastuzumab deruxtecan 1tisagenlecleucel 1pembrolizumab 1obinutuzumab 1niraparib 1nilotinib 1isatuximab 1acalabrutinib 1Zymosan 1Whole-Body Irradiation 1Trastuzumab 1Sodium Chloride 1Sirolimus 1Radiotherapy 1Pentostatin 1NKTR-255 1Mycophenolic Acid 1Melphalan 1Magnetic Resonance Imaging 1Immunotherapy 1Imatinib Mesylate 1Histamine Antagonists 1Exercise Test 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm, Residual × Magnetic Resonance Imaging × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡